Recalls and alerts more than 4 years old are automatically archived. While this information can still be accessed in the database, it has not been altered or updated since it was archived. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats by contacting us.
Information Update - New safety information on injectable gadolinium-based contrast agents used in MRI scans
- Starting date:
- January 5, 2017
- Posting date:
- January 6, 2017
- Type of communication:
- Information Update
- Source of recall:
- Health Canada
- New safety information
- General Public
- Identification number:
OTTAWA – Health Canada has conducted a safety review of gadolinium-based contrast agents (GBCAs) due to growing scientific evidence that gadolinium may accumulate in the brain following multiple contrast-enhanced magnetic resonance imaging (MRI) scans.
Although no health consequences have been identified with gadolinium accumulation in the brain, Health Canada will be working with Canadian manufacturers to update the labelling of GBCAs to include this new information.
Gadolinium is a chemical element and a component of dyes used to enhance contrast and improve radiology images. GBCAs are administered by injection and used for MRI scans when needed.
After injection, gadolinium is eliminated through the kidneys (in urine) and for some of the agents also through the liver, but small amounts may stay in different parts of the body, including the brain. Gadolinium accumulation in the brain has been found in patients both with and without kidney disease.
To date, Health Canada has not received any adverse event reports related to gadolinium accumulation in the brain.
Patients and caregivers should talk to their health care professionals if they have questions about the use of GBCAs with MRIs for their individual health circumstances.
Health professionals are advised to:
- limit the use of GBCAs to situations where the contrast agent is considered necessary,
- use the lowest effective dose, and
- assess the benefits and any potential risks to individual patients before administering repeated doses of GBCAs.
Health Canada is also advising health care professionals that the available scientific evidence suggests that gadolinium accumulation in the brain is higher with the use of linear agents than with the use of macrocyclic agents, but it has occurred with both types.
The gadolinium-based contrast agents authorized for sale in Canada are (in alphabetical order):
- DOTAREM (gadoterate meglumine) - macrocyclic agent
- GADOVIST (gadobutrol) - macrocyclic agent
- MAGNEVIST (gadopentetate dimeglumine) - linear agent
- MultiHance (gadobenate dimeglumine) - linear agent
- OMNISCAN (gadodiamide) - linear agent
- OPTIMARK (gadoversetamide) - linear agent
- PRIMOVIST (gadoxetate disodium) - linear agent
- ProHance (gadoteridol) - macrocyclic agent
Health Canada is continuing its monitoring and evaluation of the risk of gadolinium accumulation in the brain associated with the use of GBCAs and will inform Canadians again as required.
Report health or safety concerns
To report a side effect to a health product to Health Canada:
- Call toll-free at 1-866-234-2345
- Visit Health Canada's Web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax.
For more informationRelated links:
- Updated Safety Information for Gadolinium-Based Contrast Agents
- Gadolinium-Containing Contrast Agents - Update on Nephrogenic Systemic Fibrosis/Nephrogenic Fibrosing Dermopathy (NSF/NFD)
- OPTIMARK (gadoversetamide injection) – Association with Nephrogenic Systemic Fibrosis (NSF) in Patients with Renal Impairment
- Health Canada advises Canadians of safety issues related to gadolinium-containing contrast agents used in magnetic resonance imaging (MRI)
- Association of Omniscan™ (Gadodiamide) and Nephrogenic Systemic Fibrosis/Nephrogenic Fibrosing Dermopathy (NSF/NFD) - GE Healthcare Canada
- Date modified: